Posted by Michael Wonder on 30 Sep 2025
AbbVie submits biologics license application to US FDA for pivekimab sunirine - an investigational antibody-drug conjugate to treat rare cancer with limited treatment options
30 September 2025 - Biologics license application based on data from the global Phase 1/2 CADENZA trial.
AbbVie today announced submission of a new biologics license application to the US FDA for approval of investigational pivekimab sunirine for treatment of blastic plasmacytoid dendritic cell neoplasm.
